Advertisement

Topics

Latest "Ganaxolone Phase Data Supports Progressing Phase Patients With" News Stories

03:43 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Ganaxolone Phase Data Supports Progressing Phase Patients With" found in our extensive news archives from over 250 global news sources.

More Information about Ganaxolone Phase Data Supports Progressing Phase Patients With on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Ganaxolone Phase Data Supports Progressing Phase Patients With for you to read. Along with our medical data and news we also list Ganaxolone Phase Data Supports Progressing Phase Patients With Clinical Trials, which are updated daily. BioPortfolio also has a large database of Ganaxolone Phase Data Supports Progressing Phase Patients With Companies for you to search.

Showing "Ganaxolone Phase Data Supports Progressing Phase Patients With" News Articles 1–25 of 46,000+

Thursday 20th September 2018

NetScientific: ProAxsis products selected for large-scale respiratory study

The BRIDGE study, funded by the European Respiratory Society, will be conducted over three years and involve 1,000 patients suffering from bronchiectasis across Europe


4SC AG: Domatinostat plus chemotherapy - Overcoming drug resistance

DGAP-News: 4SC AG / Key word(s): Conference 20.09.2018 / 07:30 The issuer is solely responsible for the content of this announcement. 4SC AG: Domatinostat plus chemotherapy - Overcoming drug resistance Domatinostat (4SC-202) renders cancer cell lines more susceptible to chemotherapy treatment Poster presentation at the SIC Annual Meeting, 19-22 September 2018, Milan, Italy   ...

Vaxart Inc VXRT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummaryVaxart Inc Vaxart is a clinical stage biotechnology company which develops oral recombinant protein vaccines based on its proprietary oral vaccine delivery platform to treat infections. The company develops tablet vaccines for seasonal and pandemic influenza, norovirus, and respiratory syncytial virus RSV. Vaxart's vaccine delivery platform encompasses vectoradjuvant combination, which can ...


Fibrocell Science Inc FCSC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryFibrocell Science Inc Fibrocell Science is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company's product pipeline comprises FCX007, a lead candidate for the treatment of recessive dystrophic epidermolysis bullosa; FCX013 for linear scleroderma; and a research program for the treatment of arthri...

DaVita Inc DVA Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryDaVita Inc DaVita, formerly DaVita HealthCare Partners Inc., is a provider of dialysis services and integrated health care delivery and management services. The company is a provider of dialysis services in the US for patients with chronic kidney failure and endstage renal disease ESRD. It also provides integrated health care delivery and management services. DaVita offers ancillary service...

Wednesday 19th September 2018

Researchers develop fast detection strategy to know type of virus acquired by patients

Even tiny amounts of viruses can have disastrous consequences. RNA identification can reveal the type of virus present.

Health care companies' data could enable more accurate flu season forecasts

In an era when for-profit companies collect a wealth of data about us, new research from The University of Texas at Austin shows that data collected by health care companies could -- if made available to researchers and public health agencies -- enable more accurate forecasts of when the next flu season will peak, how long it will last and how many people will get sick.

UBX To Report Phase I Data In Q1, NVTA On Watch, NTGN Faces Busy Year Ahead

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

JP $ASND Bigger picture,continue to see Ascendis evolving into a company with R&D productivity, and ultimately valuation, consistent with a platform company &see successful phase III GH data as key to validating potential of the TransCon platform and unlo

JP $ASND Bigger picture,continue to see Ascendis evolving into a company with R&D productivity, and ultimately valuation, consistent with a platform company &see successful phase III GH data as key to validating potential of the TransCon platform and unlocking additional value.

JP $APTX lead asset,NYX-2925, in development treatment of painful DPN &fibromyalgia,with topline phase II data expected1H19. Bigger picture, see potential for Aptinyx’s NMDA receptor modulator platform to demonstrate broad applicability in multiple indi

JP $APTX lead asset,NYX-2925, in development treatment of painful DPN &fibromyalgia,with topline phase II data expected1H19. Bigger picture, see potential for Aptinyx’s NMDA receptor modulator platform to demonstrate broad applicability in multiple indications,substantial upside

Percentages of patients achieving ≥30% reduction in liver fat, which KOLs believe highly associated with histologic response in NASH, are 76.9%, 90.9% and 18.2% in 10mg QOD VK2809, 10mg QD VK2809, and placebo groups, respectively. $VKTX

Percentages of patients achieving ≥30% reduction in liver fat, which KOLs believe highly associated with histologic response in NASH, are 76.9%, 90.9% and 18.2% in 10mg QOD VK2809, 10mg QD VK2809, and placebo groups, respectively. $VKTX

STIFEL $NBIX Deep Dive on Tourette's: Raising Our Probability of Valbenazine Success, NBIX Target Price to $142 Ahead of 4Q18 Data-stock currently prices in a 40%-50% probability; thus, on success/failure, we estimate an up/down share reaction of +15% or

STIFEL $NBIX Deep Dive on Tourette's: Raising Our Probability of Valbenazine Success, NBIX Target Price to $142 Ahead of 4Q18 Data-stock currently prices in a 40%-50% probability; thus, on success/failure, we estimate an up/down share reaction of +15% or -12% to -15%.

Decoding the phase structure of QCD via particle production at high energy

T cells in patients with narcolepsy target self-antigens of hypocretin neurons

GI Dynamics Announces AUD $6.9m Private Placement to be Completed in Two Tranches

GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary Interests (CDIs) of the Company (representing 6,944,445 shares of common stock) at an issue price of ...

MTEM Abuzz, TLRY Up 1,240% In 2 Months, ALT Awaits Anthrax Data In Q4

The following are some of today's top gainers in the pharma/biotech sector.

Nephropathy Global Clinical Trials Review, H1, 2018 [Report Updated: 31032018] Prices from USD $2500

Nephropathy Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Nephropathy Global Clinical Trials Review, H1, 2018" provides an overview of Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across ...

[Articles] Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis

Patients with HE juvenile Huntington's disease differ clinically from patients with LE juvenile Huntington's disease or adult-onset Huntington's disease, suggesting reclassification of this particularly aggressive form of Huntington's disease might be required.

Pelago Bioscience AB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17042018] Prices from USD $250

SummaryPelago Bioscience AB Pelago Bioscience is a developer of patented cellular thermal shift assay for use in determination and quantification of drugtarget interactions. The company utilizes patented CETSA technology which enables direct, in situ physiologically relevant measurements of target engagement on target proteins in lysate, intact cells and tissue samples. Pelago Bioscience delivers ...

Can a common heart condition cause sudden death?

(Gladstone Institutes) About one person out of 500 has a heart condition known as hypertrophic cardiomyopathy (HCM). This condition causes thickening of the heart muscle and results in defects in the heart's electrical system. Under conditions of environmental stress such as exercise, HCM can result in sudden death. In other cases, patients may go undiagnosed, with their heart function declining g...

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018

  Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 Strengthening of NBTXR3 data showing the potential impact on survival in elderly and frail patients with locally advanced head and neck cancersBiomarker analysis from soft tissue sarcoma clinical trial and new preclinical data supporting NBTXR3 mechanism of action in i...

Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)

Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR), a biopharma company (formerly known as ThromboGenics) focused on developing treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease, announces that it has enrolled the first patient in a Phase 2 open-label multi-centre study evaluating the efficacy and safety of intravitreal THR-317, an ...

ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer

LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named ‘TRYbeCA1’, evaluating its ...

Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. IDWeek 2018October 3-7, 2018San Francisco, CA  USA Iclaprim data will be presented at the conference in a poster, entitled:  A Pool...

Increased expression of miR-33a in monocytes from Mexican hypertensive patients in elevated carotid intima-media thickness


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks